Hormonal treatment for breast cancer reduces the risk of dementia and Alzheimers

In a scientific study, it was reported that HMT treatment used to treat breast cancer was associated with low risk for Alzheimer’s and dementia later in life. The study, the results of which were published in the journal “Gamma”, which is one of the largest studies of its kind, found that the connection by 7%, despite the association of hormone modification medicine to protect the development of dementia in general by 7%and vary according to the breed. The results of the researchers emphasize the importance of realizing the individual factors of the patient when prescribing medication or developing treatment for breast cancer. About two -thirds of breast cancer patients suffer from crops with positive hormonal receptors, which means they grow in response to estrogen or progesterone. The estrogen hormone has many functions in the body as it maintains the reproductive system and female properties in women, contributing to the maintenance of bone health and the health of the circulatory system and other surgeries, and is found in men and women, but it is produced in larger quantities in female bodies. As for the hormone progesterone, it plays a decisive role in the balance of women’s reproductive system as it helps to organize the menstrual cycle, but it is also the uterus to receive the fertilized egg during pregnancy. For these patients, hormone modification medicine can hamper the growth of the crop by preventing hormones from being associated with these receptors. Conflicting evidence while using these drugs is related to an increase in survival, there is conflicting evidence of whether it increases or reduces the risk of Alzheimer’s disease and associated dementia, and the depleted cases characterized by memory loss, mood changes or behavior, thought problems, problem solving and distraction. In the study, the researchers used a database for people who are 65 years old and older to identify women who were diagnosed with breast cancer between 2007 and 2009 who had no previous diagnosis of dementia or a date for the use of hormonal medicine before diagnosing breast cancer. Of the 18.808 patients with the standards, 66% of them received hormonal treatment within three years after their diagnosis, while the treatment did not receive 34% of them. During an average of 12 years of succession, 24% of hormonal therapy users and 28% of non -users were injured in an outdated dementia disorder. To calculate the risk of infection with these disorders, researchers have taken into account the risk of death associated with an increased age and the duration of hormonal therapy. They also found that although the use of these treatments was linked to a general decline in the relative risk of dementia disorders, its preventative effect was more visible in patients between the ages of 65 to 69 years and reduced by age. In patients over 80, there was an increasing risk of dementia in users of hormonal modification treatments. The study indicates that younger women can benefit more than hormonal treatments in reducing the risk of Alzheimer’s disease and other types of dementia, while the benefits of these treatments for women at the age of 75 and older have decreased, especially if identified as white skin. Women with black fins had a 24% decrease in hormonal treatments between the age of 65 to 74 years by the relative risk of dementia, and this percentage decreased to 19% to the age of 75. The risk of infection with these disorders also dropped by 11% in women with a white skin who is between 65 to 74 years old with the use of hormonal treatments, but this useful relationship has disappeared. The researchers say that women with black skin have higher breast cancer. The researchers do not know exactly the mechanisms behind these differences.